№ lp_1_2_65519
File format: docx Character count: 35299 File size: 129 KB
The document presents an economic evaluation regarding the higher-than-expected number of icatibant injections used per patient in comparison with previous forecasts, in the context of the Australian PBS funding for hereditary angioedema treatment.
Year: 2015
Region / city: Australia
Topic: Pharmacoeconomic Evaluation, Pharmaceutical Policy
Document Type: Submission
Organization / Institution: Pharmaceutical Benefits Advisory Committee (PBAC), Shire Australia Pty Ltd
Author: Shire Australia Pty Ltd
Target Audience: Healthcare professionals, policymakers
Period of Effectiveness: 2015-2020
Approval Date: July 2015
Revision Date: None indicated
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Changes have been made to this item. Details of the corrigendum are at the end of this document.5.18 RELUGOLIX WITH ESTRADIOL AND WITH NORETHISTERONE ACETATE, Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 0.5 mg, Ryeqo®, Gedeon Richter Australia Pty Ltd.
Year: 2024
Region / City: Australia
Subject: Endometriosis treatment
Document Type: Medical submission
Organization: Gedeon Richter Australia Pty Ltd
Author: Gedeon Richter Australia Pty Ltd
Target Audience: Medical professionals, health authorities
Period of validity: Ongoing
Approval Date: 31 January 2024
Modification Date: Not specified
Patient Group Direction (PGD) for the Supply and/or Administration of Subcutaneous Medroxyprogesterone Acetate (SC-DMPA) Injection
Note: Version Number 2.3
Year: 2025
Region / City: United Kingdom
Theme: Sexual and Reproductive Health
Document Type: Patient Group Direction (PGD)
Organisation: Faculty of Sexual and Reproductive Health (FSRH)
Author: Dr. Cindy Farmer, Michelle Jenkins, Elaine Scott, Kalpesh Thakrar, Sim Sesane, Tanya Lane, Kate Devonport, Chetna Parmar, Carmel Lloyd, Clare Livingstone, Portia Jackson, Kirsty Armstrong, Dipti Patel, Emma Anderson, Alison Crompton, Lisa Knight, Bola Sotubo, Tracy Rogers, Sandra Wolper, Jo Jenkins, Rosie Furner
Target Audience: Registered healthcare professionals authorised to practice under this PGD
Period of Effect: May 2023 - April 2026
Approval Date: December 2022
Review Date: October 2025
Expiry Date: April 2026
LANREOTIDE, Injection 60 mg (as acetate) in single dose pre-filled syringe, Injection 90 mg (as acetate) in single dose pre-filled syringe, Injection 120 mg (as acetate) in single dose pre-filled syringe, Mytolac®, Amdipharm Mercury (Australia) Pty Limited
Year: 2022
Region / City: Australia
Topic: Medicinal Product Submission
Document Type: Submission for Pharmaceutical Listing
Organization / Institution: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Not specified
Target Audience: Healthcare professionals, policy makers
Period of Validity: Not specified
Approval Date: 10 August 2022
Date of Changes: Not specified
Rationale for Initiation, Continuation and Discontinuation RICaDPrescribing information for Relugolix-estradiol-norethisterone acetate (Ryeqo®) for treating moderate to severe symptoms of uterine fibroids
Year: 2026
Region / City: United Kingdom
Theme: Pharmaceutical Treatment
Document Type: Prescribing Information
Organization: NHS
Author: Dr. Joanne Ritchie
Target Audience: Healthcare professionals, specifically specialists and GPs
Period of Validity: Not specified
Approval Date: Not specified
Modification Date: Not specified
Contraindications: Venous thromboembolic disorder, arterial thromboembolic disease, known thrombophilic disorders, known osteoporosis, headaches with focal neurological symptoms, pregnancy, breastfeeding
Monitoring: DEXA scan recommended after 1 year of treatment
Special Warnings/Precautions: Use of non-hormonal contraception for at least 1 month after initiation
Adverse Effects: Hot flushes, headache
Primary Care responsibilities for continuation: Prescribe as recommended, seek advice from the specialist if needed
Specialist Service responsibilities for initiation: Discuss benefits and side effects with the patient, initiate treatment and monitor
Criteria for Discontinuation: Menopause, increase in migraine frequency, ATE/VTE events, acute liver deterioration
Date of Initiation: Not specified
Communication: Contact details for the specialist and hospital pharmacy provided
STANDARD OPERATING PROCEDURE Ethyl Acetate
Note: Year
Hospital Formulary Submission Pack for REZZAYO® (rezafungin acetate)
Year: 2023
Region / city: UK
Topic: Healthcare, Pharmaceuticals, Antifungal Treatment
Document Type: Prescribing Information
Organization: NAPP Pharmaceuticals Ltd
Author: NAPP Pharmaceuticals Ltd
Target Audience: UK Healthcare Professionals
Period of validity: Not specified
Date of approval: Not specified
Date of changes: Not specified
Supply and administration of subcutaneous medroxyprogesterone acetate (SC-DMPA) under Patient Group Direction in the UK, version 3.0, January 2026
Year: 2026
Region / City: United Kingdom
Subject: Reproductive health; contraceptive administration
Document type: Patient Group Direction (PGD)
Authorising body: College of Sexual and Reproductive Healthcare (CoSRH)
PGD development group: Reproductive Health PGDs Short Life Working Group (SLWG)
Approving organisations: NHS Trusts and local health authorities
Target audience: Registered healthcare professionals authorised to use the PGD
Effective date: 1 May 2026
Review date: 1 November 2028
Expiry date: 30 April 2029
Version: 3.0
Change history: Includes updates on contraindications, cautions, and terminology alignment with UKMEC 2025 and CoSRH guidance
Training requirements: Authorised HCPs must complete specified education and competency assessment
Legal compliance: Must be signed by senior doctor, senior pharmacist, and organisational representative
Description: Official national PGD detailing the conditions, contraindications, administration procedure, and authorisation requirements for SC-DMPA use by qualified healthcare professionals, including a comprehensive version history and governance framework.
Inclusion and Exclusion Criteria for Phase 1/2 Study of Onalespib and Abiraterone Acetate in Castration-Resistant Prostate Cancer
Year: 2021
Region / City: Not specified
Topic: Clinical study, oncology, prostate cancer
Document Type: Study Protocol
Organization / Institution: Not specified
Author: Not specified
Target Audience: Medical professionals, clinical researchers
Effective Period: Not specified
Approval Date: Not specified
Modification Date: Not specified
Detection of Methyltestosterone and Trenbolone Acetate Hormones Residues in Nile Tilapia (Oreochromis niloticus)
Year: 2009
Region / City: Cairo, Giza
Topic: Hormone residues in fish
Document Type: Research Study
Organization / Institution: Faculty of Veterinary Medicine, Benha University; Animal Health Research Institute, Dokki, Giza
Author: Hemmat M; Reham A; Omaima M D; Asmaa E H
Target Audience: Researchers, Aquaculture Specialists
Action Period: Not specified
Approval Date: Not specified
Modification Date: Not specified
Topics: ICATIBANT FIRAZYR ACETATE